. Author manuscript; available in PMC: 2020 Mar 15.

Published in final edited form as: Int Arch Allergy Immunol. 2019 Mar 15;179(1):21–30. doi: 10.1159/000496162

TABLE 2.

Reported adverse events

Adverse event, n (%)	Active (n = 14)	Placebo (n = 12)	P value

Headache	0	2 (16.6)	.10
Musculoskeletal	3(21.4)	1 (8.3)	.36
Infection	5 (35.7)	5(41.7)	.76
Sleep impairment	1 (7.1)	1 (8.3)	.91
Respiratory disorders (non-infectious)	0	0	–
Gastrointestinal disorders	5 (35.7)	2 (16.6)	.34
Blood disorders	0	0	–
Eye and vision disorders	0	1 (8.3)	.27
Cardiovascular disorders	1 (7.1)	1 (8.3)	.91
Renal disorders	0	0	–
Reproductive disorders	0	0	–
Skin or hair disorders	0	2 (16.6)	.10
Immunologic disorders	0	0	–

P values are based on Chi-Square test for the categorical variables